Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527684 | 1.00 | ALDH1A1 (0.68) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL30546900 | 1.00 | ALDH1A1 (0.68) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL844653 | 1.00 | ALDH1A1 (0.68) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| Methane SCHEMBL28312499 | 0.98 | ALDH1A1 (0.66) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL24591583 | 0.94 | ALDH1A1 (0.60) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL7793951 | 0.93 | ALDH1A1 (0.67) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL29366782 | 0.93 | ALDH1A1 (0.67) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL1715242 | 0.93 | ALDH1A1 (0.71) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL18125579 | 0.89 | ALDH1A1 (0.67) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL12441429 | 0.89 | ALDH1A1 (0.67) | ALDH1A1TP53TSHRHIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531890-B1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR PRODUCING STRUCTURE, AND LIQUID DISCHARGE HEAD | CANON KK (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-20080213833-A1 | Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates | OXRANE (UK) LTD. (GB) | 2008-09-04 | — | — | US | disclosed |
| EP-1885849-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE GLYCIDYL ETHERS AND OPTICALLY ACTIVE VICINAL DIOLS FROM RACEMIC SUBSTRATES | Oxyrane UK Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006109198-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE GLYCIDYL ETHERS AND OPTICALLY ACTIVE VICINAL DIOLS FROM RACEMIC SUBSTRATES | OXYRANE UK LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| US-6242450-B1 | SUBSTITUTED PIPERIDINES | ELI LILLY AND COMPANY | 2001-06-05 | — | — | US | disclosed |
| WO-2000006082-A2 | TREATMENT OF ANXIETY DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006166-A1 | 5-HT1F ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976746-A1 | 5-HT1F antagonists | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0976747-A2 | Use of 5HT-1F receptor antagonists for treating anxiety disorders | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213833-A1 | Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates | GALE, DERA, GNE | ALDH1A1 663/4885TP53 4052/4885TSHR 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.